Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations

References

• Focosi D, Farrugia A. Urgent need to regulate convalescent plasma differently from thawed plasma,
   Google Scholar
• Focosi D, Anderson AO, Tang JW, et al. Convalescent Plasma Therapy for COVID-19: state of the Art. Clin Microbiol Rev. 2020;33(4):e00072–00020.
   PubMed Web of Science ®Google Scholar
• Gonzalez SE, Regairaz L, Salazar M, et al. Timing of Convalescent plasma administration and 28-day mortality for COVID-19 pneumonia. medrXiv 2021;2002(2002):21250758 (2021.
   Google Scholar
• Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021(11). doi:10.1056/NEJMoa2031893.
   Web of Science ®Google Scholar
• Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021;7. Epub ahead of print. DOI:10.1056/NEJMoa2033700
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020;95(9):1888–1895. .
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2020;384(3):238–251. .
   PubMed Web of Science ®Google Scholar
• Focosi D, Franchini M, Tuccori M. The road towards polyclonal anti-SARS-CoV-2 immunoglobulins (hyperimmune serum) for passive immunization in COVID19. Life (Basel). 2021 Feb 15;11(2):144.
   Google Scholar
• FDA. Recommendations for Investigational COVID-19 Convalescent Plasma. (Ed.^(Eds)
   Google Scholar
• Farcet MR, Karbiener M, Schwaiger J, et al. Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic. J Infect Dis. 2021. DOI:10.1093/infdis/jiab142
   PubMed Web of Science ®Google Scholar
• Focosi D, Franchini MCOVID. 19 convalescent plasma therapy: hit fast, hit hard! Vox Sang. 2021. DOI:10.1111/vox.13091
   PubMed Web of Science ®Google Scholar
• Meyts I, Bucciol G, Quinti I, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147(2):520–531. .
   PubMed Web of Science ®Google Scholar
• Babaha F, Rezaei N. Primary Immunodeficiency Diseases in COVID-19 Pandemic: a Predisposing or Protective Factor? Am J Med Sci. 2020;360(6):740–741.
   PubMed Web of Science ®Google Scholar
• Delavari S, Abolhassani H, Abolnezhadian F, et al. Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency. J Clin Immunol. 2021;41(2):345–355. .
   PubMed Web of Science ®Google Scholar
• Quinti I, Lougaris V, Milito C, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146(1):211–213.e214. .
   PubMed Web of Science ®Google Scholar
• Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020;31(5):565–569. .
   PubMed Web of Science ®Google Scholar
• Jin H, Reed JC, Liu STH, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(10):3594–3596.e3593. .
   PubMed Web of Science ®Google Scholar
• Loh SY, Bassett J, Hoodless EJ, et al. COVID-19 reinfection in a patient with X-linked agammaglobulinaemia. BMJ Case Rep. 2021;14:3.
   Google Scholar
• London J, Boutboul D, Lacombe K, et al. Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy. J Clin Immunol. 2021 Feb;41(2):356-361.
   Google Scholar
• Fill L, Hadney L, Graven K, et al. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125(1):112–114.
   PubMed Web of Science ®Google Scholar
• Nsc VO, Hanners NW, Sue PK, et al. SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency. Clin Immunol. 2021;224:108662.
   PubMed Web of Science ®Google Scholar
• Pozzi MR, Baronio M, Janetti MB, et al. Fatal SARS-CoV-2 infection in a male patient with Good’s syndrome. Clin Immunol. 2021;223:108644.
   PubMed Web of Science ®Google Scholar
• Mira E, Yarce OA, Ortega C, et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(8):2793–2795. .
   PubMed Web of Science ®Google Scholar
• Iaboni A, Wong N, Betschel SDA. Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma. J Clin Immunol. 2021 Feb 6;1-3.
   Google Scholar
• Delgado-Fernández M, García-Gemar GM, Fuentes-López A, et al. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature. Enferm Infecc Microbiol Clin. 2021. DOI:10.1016/j.eimc.2021.01.013.
   Web of Science ®Google Scholar
• Milošević I, Jovanović J, Stevanovic O. Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. J Infect Developing Countries. 2020;14(11):1248–1251.
   Google Scholar
• Hovey JG, Tolbert D, Howell D. Bruton’s Agammaglobulinemia and COVID-19. Cureus. 2020;12(11):e11701.
   PubMed Web of Science ®Google Scholar
• Ribeiro LC, Benites BD, Ulaf RG, et al. Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma. Allergy Asthma Clin Immunol. 2021;17(1):14. .
   PubMed Web of Science ®Google Scholar
• Bearden D, Collett M, Quan PL, et al. Enteroviruses in X-Linked Agammaglobulinemia: update on Epidemiology and Therapy. J Allergy Clin Immunol Pract. 2016;4(6):1059–1065.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745. .
   PubMed Web of Science ®Google Scholar
• He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–1645. .
   PubMed Web of Science ®Google Scholar
• Aries JA, Davies JK, Auer RL, et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol. 2020;190(2):e64–e67. .
   PubMed Web of Science ®Google Scholar
• Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34(11):3047–3049. .
   PubMed Web of Science ®Google Scholar
• Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848. .
   PubMed Web of Science ®Google Scholar
• Focosi D, Franchini M. COVID19 neutralizing antibody-based therapies in humoral immune deficiencies: a narrative review. Transfus Apher Sci. 2021 Jan 27;103071.
   Google Scholar
• Avanzato VA, Matson MJ, Seifert SN, et al. Case Study: prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020(7). doi:10.1016/j.cell.2020.10.049.
   PubMed Web of Science ®Google Scholar
• Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295. .
   PubMed Web of Science ®Google Scholar
• Khan AM, Ajmal Z, Raval M, et al. Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: a Management Challenge. Cureus. 2020;12(8):e9629.
   PubMed Web of Science ®Google Scholar
• Fung M, Nambiar A, Pandey S, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transplant Infect Dis. 2020; (2):e13477. DOI:10.1111/tid.13477.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Liu Y, Guo YG, et al. Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis. Turk J Haematol. 2020(1). doi:10.4274/tjh.galenos.2020.2020.0400.
   Web of Science ®Google Scholar
• Lancman G, Mascarenhas J, Severe B-NM. COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):131.
   PubMed Web of Science ®Google Scholar
• Luetkens T, Metcalf R, Planelles V, et al. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv. 2020;4(19):4864–4868. .
   PubMed Web of Science ®Google Scholar
• Karataş A, İnkaya A, Demiroğlu H, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci. 2020;59(5):102871.
   PubMed Web of Science ®Google Scholar
• Wright Z, Bersabe A, Eden R, et al. Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):66-68.
   Google Scholar
• Clark E, Guilpain P, Filip IL, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol. 2020;190(3):e154–e156. .
   PubMed Web of Science ®Google Scholar
• Baang JH, Smith C, Mirabelli C, et al. Prolonged SARS-CoV-2 replication in an immunocompromised patient. J Infect Dis. 2021 Jan 4;223(1):23-27.
   Google Scholar
• Malsy J, Veletzky L, Heide J, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa1637.
   Web of Science ®Google Scholar
• Betrains A, Godinas L, Woei AJF, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2020(6). doi:10.1111/bjh.17266.
   PubMed Web of Science ®Google Scholar
• Moore JL, Ganapathiraju PV, Kurtz CP, et al. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. Am J Case Rep. 2020;21:e927812.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Caprioli C, Weber A, et al. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma. 2021;1–9. DOI:10.1080/10428194.2021.1872070
   Web of Science ®Google Scholar
• Balashov D, Trakhtman P, Livshits A, et al. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation. Transfus Apher Sci. 2021 Feb;60(1):102983.
   Google Scholar
• Thompson MA, Henderson JP, Shah PK, et al. Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19. medrXiv 2021;2002(2005):21250953 (2021.
   Google Scholar
• Jeyaraman P, Agrawal N, Bhargava R, et al. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies. Transfus Apher Sci. 2021 Feb 3:103075.
   Google Scholar
• Tremblay D, Seah C, Schneider T, et al. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. Cancer Med. 2020;9(22):8571–8578. .
   PubMed Web of Science ®Google Scholar
• Çınar OE, Sayınalp B, Aladağ Karakulak E, et al. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. Transfus Apher Sci. 2020;59(5):102821.
   PubMed Web of Science ®Google Scholar
• Senefeld JW, Klassen SA, Ford SK, et al. Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency. medrXiv 2020;2011(2008):20224790 (2020.
   Google Scholar
• Kenig A, Ishay Y, Kharouf F, et al. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clin Immunol. 2021 Apr 7;227:108723.
   Google Scholar
• Rodionov RN, Biener A, Spieth P, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet. 2021;2(4):e138. . Microbe
   Web of Science ®Google Scholar
• Jamir I, Lohia P, Pande RK, et al. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Ann Hepatobiliary Pancreat Surg. 2020;24(4):526–532.
   PubMedGoogle Scholar
• Lima B, Gibson GT, Vullaganti S, et al. COVID-19 in recent heart transplant recipients: clinicopathologic features and early outcomes. Transplant Infect Dis. 2020;22(5):e13382. .
   PubMed Web of Science ®Google Scholar
• Naeem S, Gohh R, Bayliss G, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. Transplant Infect Dis. 2020; (1):e13451. DOI:10.1111/tid.13451.
   PubMedGoogle Scholar
• Jiang J, Miao Y, Zhao Y, et al. Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications. Clin Transplant. 2020;34(9):e14025. .
   PubMed Web of Science ®Google Scholar
• NHS Blood and Transplant N. One of the first COVID-19 convalescent plasma recipients supports donor appeal.
   Google Scholar
• Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev (Orlando). 2020;35(1):100588.
   PubMedGoogle Scholar
• Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med. 2020 Dec 24;383(26):2586-2588.
   Google Scholar
• Bazykin G, Stanevich O, Danilenko D et al. Emergence of Y453F and Δ69-70HV mutations in a lymphoma patient with long-term COVID-19. (Ed.^(Eds) (2021)
   Google Scholar
• Borges V, Isidro J, Cunha M et al. Long-term evolution of SARS-CoV-2 in an immunocompromised patient with non-Hodgkin lymphoma. (Ed.^(Eds)
   Google Scholar
• Truong TT, Ryutov A, Pandey U, et al. Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. bioRxiv. 2020 Dec 28:2020.12.28.424451.
   Google Scholar
• Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020 Dec 28:2020.12.28.424451.
   Google Scholar
• Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. biorXiv [Preprint]. (Ed.^(Eds) (2021) 2021.2001.2015… 426911
   Google Scholar
• Valesano AL, Rumfelt KE, Dimcheff DE, et al. Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts. 2021;2001(2019):427330 (2021.
   Google Scholar
• Kemp SA, Collier DA, Datir R, et al. Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. Nature. 2020;2020(2012):2005.20241927.
   Google Scholar
• Franchini M, Marano G, Velati C, et al. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sang. 2020;116(1):136–137.
   PubMed Web of Science ®Google Scholar